Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39 by Roland, W.S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/153981
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
RESEARCH ARTICLE
Snooker Structure-Based Pharmacophore
Model Explains Differences in Agonist and
Blocker Binding to Bitter Receptor hTAS2R39
Wibke S. U. Roland1¤a, Marijn P. A. Sanders2¤b, Leo van Buren3, Robin J. Gouka3,
Harry Gruppen1, Jean-Paul Vincken1, Tina Ritschel2*
1 Laboratory of Food Chemistry, Wageningen University, 6708WGWageningen, The Netherlands, 2
Computational Discovery and Design Group (CDD), Centre for Molecular and Biomolecular Informatics
(CMBI), Radboud university medical center, 6500 HB Nijmegen, The Netherlands, 3 Unilever R&D, 3133 AT
Vlaardingen, The Netherlands
¤a Current address: NIZO food research, 6718 ZB Ede, The Netherlands
¤b Current address: Aorta business intelligence, 5145 RMWaalwijk, The Netherlands
* tina.ritschel@radboudumc.nl
Abstract
The human bitter taste receptor hTAS2R39 can be activated by many dietary (iso)flavo-
noids. Furthermore, hTAS2R39 activity can be blocked by 6-methoxyflavanones, 4’-fluoro-
6-methoxyflavanone in particular. A structure-based pharmacophore model of the
hTAS2R39 binding pocket was built using Snooker software, which has been used suc-
cessfully before for drug design of GPCRs of the rhodopsin subfamily. For the validation of
the model, two sets of compounds, both of which contained actives and inactives, were
used: (i) an (iso)flavonoid-dedicated set, and (ii) a more generic, structurally diverse set. Ag-
onists were characterized by their linear binding geometry and the fact that they bound
deeply in the hTAS2R39 pocket, mapping the hydrogen donor feature based on T5.45 and
N3.36, analogues of which have been proposed to play a key role in activation of GPCRs.
Blockers lack hydrogen-bond donors enabling contact to the receptor. Furthermore, they
had a crooked geometry, which could sterically hinder movement of the TM domains upon
receptor activation. Our results reveal characteristics of hTAS2R39 agonist and bitter block-
er binding, which might facilitate the development of blockers suitable to counter the bitter-
ness of dietary hTAS2R39 agonists in food applications.
Introduction
Bitter taste is perceived via bitter taste receptors located in taste buds on the tongue. Amongst
the 25 human bitter taste receptors (hTAS2Rs), ligands have been identified for 21 hTAS2Rs.
[1,2] The bitter taste receptor hTAS2R39 has been identified as one of the sensors of dietary
phenolics, comprising the classes of flavonoids and isoflavonoids.[3,4] Many phenolics have
been associated with the healthiness of fruits and vegetables, but inevitably also with bitterness,
which can affect consumer acceptance of such products. In order to counter this off-taste,
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different strategies can be employed. Traditionally, undesired bitter taste can be masked by ad-
dition of flavors or tastants. A second approach in reducing bitterness is to prevent contact of
the bitter compounds with the bitter taste receptor by techniques such as encapsulation, molec-
ular inclusion or complexation. It has been shown that phenolics can be bound to proteins like
casein, leading to decreased activation of bitter taste receptor hTAS2R39 and to decreased bit-
terness perception in vivo.[5] A third strategy is the application of so-called bitter blockers (or
antagonists). For hTAS2R39, it has been found that 6-methoxyflavanones (the synthetic 4’-
fluoro-6-methoxyflavanone, in particular) can decrease the response towards diverse bitter
compounds (or agonists).[6] Agonists and blockers can bind to the receptor, but only the bind-
ing of agonists results in receptor activation. An intriguing question is whether blockers and
agonists have different binding modes to hTAS2R39, provoking different responses in signal
transduction. So far, this question has remained unanswered.
Bitter taste receptors belong to the family of G-protein coupled receptors (GPCRs).[7]
Amongst the GPCRs, bitter receptors form their own subfamily, denoted ‘taste 2’, and until
now, no crystal structure of any bitter taste receptor is available. In recent years, approaches to
elucidate the structures of several members of the hTAS2R family by homology modeling
have been described, often in combination with molecular docking studies. These included
hTAS2R1 [8,9], hTAS2R10 [10], hTAS2R16 [11,12], hTAS2R31 [13], hTAS2R38 [11,14,15,
16,17], hTAS2R43 [13], and hTAS2R46 [18,19]. Most publications suggested the presence of
a single binding pocket within the trans-membrane (TM) region, consisting of seven TM do-
mains (numbered I to VII), of the respective bitter receptors. Predicted or experimentally de-
termined amino acid residues involved in agonist interaction were reported to be accumulated
in TM III, TM VI and TM VII.[20] So far, few bitter taste receptor antagonists have been
identified and modeling has scarcely been applied.[6,13,21,22,23,24]
Snooker has been proven to be a powerful structure-based approach to generate pharmaco-
phore hypotheses based on the properties of the receptor. These hypotheses have been used for
compounds binding to the extracellular side of the TM domain of the rhodopsin subfamily of
GPCRs, and can be applied in principle for all subfamilies of GPCRs.[25] Structure-based
modeling has several advantages over ligand-based modeling approaches: i) the model is not
biased towards known ligands, ii) a hypothesis of the protein-ligand binding mode can be
made, and iii) details about protein-ligand interactions can be retrieved.
Here, we apply Snooker to build a structure-based pharmacophore of hTAS2R39. This
pharmacophore model is purely built on the information obtained from many taste receptor
amino acid sequences and a GPCR receptor template. Using only the sequence conservation
and evolution theory, important amino acids can be identified, and their involvement in li-
gand-binding or in the receptor activation mechanism can be characterized.[26] Pharmaco-
phore models are derived from this information and do not include compound information.
The validation of the obtained pharmacophore model is based on experimental data of previ-
ously published compounds. Based on the structure-based pharmacophore, the interaction be-
tween the receptor and agonists or blockers can be described. Using this approach, the
importance in ligand binding of certain amino acids that are conserved amongst TAS2R39 ho-
mologs is demonstrated, and differences in binding modes between blockers and agonists
were identified.
Methods
Snooker
Snooker was previously developed and applied for rhodopsin-subfamily GPCRs and uses only
receptor information to build a pharmacophore model of the protein-ligand binding site. In
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the current manuscript Snooker is extended to bitter receptors, a different class of GPCRs.[25]
The approach is semi-automated and constructs a homology model of the transmembrane do-
mains. Furthermore, it prioritizes amino acids on the probability of being involved in ligand–
binding, based on an analysis of conserved residues in a multiple sequence alignment.[26] Sub-
sequently, protein features are converted to ligand space, and pharmacophore features are gen-
erated at ‘hot-spots’ of interaction features. In order to use Snooker on bitter receptor
hTAS2R39, a multiple sequence alignment of the taste receptor family, including many differ-
ent species, was obtained from GPCRDB (S2 File)[27] and uploaded to Snooker. In total
711 sequences were introduced to Snooker. The definition of the transmembrane helices of the
GPCR was manually compared to other publications [10,18,28] and no significant differences
were observed. Snooker combines several approaches and consists of eight steps:
(1) Template selection: The known GPCR crystal structure of bovine rhodopsin with PDB-
code 1GZM was used as a template for modeling.[29] For Snooker, external and internal
loops are not considered, resulting in a model of only the transmembrane helices.
(2) Homology model construction: The homology model was constructed based on the align-
ment of the TM domains with the template sequence. Snooker keeps the backbone of the
TM as in the template structure. Ballesteros andWeinstein numbering was used for the
numbering of the amino acid residues in the TM domains. This nomenclature uses the
principle that the helices are numbered from 1 to 7, and that the most conserved amino
acid residue in each helix receives the number 50. Amino acid residues are counted down-
wards in N-terminal direction and upwards in C-terminal direction. Ballesteros and Wein-
stein numbers of transmembrane helices are: TM I: 1.33–1.56; TM II: 2.40–2.65; TM III:
3.25–3.51; TM IV: 4.43–4.64; TM V: 5.38–5.63; TM VI: 6.37–6.59; TM VII: 7.34–7.56. The
alpha-helices of GPCRs are positioned in the membrane which requires hydrophobic
amino acid side chains facing towards the membrane. Therefore, the beginning of TM V
was shifted by three amino acids to ensure that hydrophobic amino acids were pointing to
the membrane and hydrophilic residues were pointing to the inside of the receptor.
(3) Rotamer sampling: The rotamers indicate the likelihood of a direction of the amino acid
residue side chains, which enables the calculation of the most probable binding pocket. De-
fault Snooker rotamers and rotamer scores were added to the initial homology model to ac-
count for possible model inaccuracy of the initial homology model. Use of an ensemble of
rotamers avoided the computational magnitude that would result from considering all
possible models, which can be obtained by combining all possible rotamer states for each
single residue. The rotamer ensemble and likelihood of occurrence of each rotamer was
subsequently used to generate both the protein- and pocket volume definition and interac-
tion features.
(4) Protein- and pocket volume definition: Because default Snooker parameters for cavity de-
tection resulted in a very small pocket, all tetrahedra with edges longer than 8.0 Å instead
of the default value of 8.5 Å were removed. All other parameters were used at
default settings.
(5) Residue scoring: Residues were scored upon ligand binding probability.[26] To determine
the ligand binding residues specific for this subfamily, a subfamily definition of receptors
q50kk9_9prim, q50kl0_pantr, q50kl2_human, q5ug17_pantr, t2r39_human,
t2r39_macmu, t2r39_panpa, and t2r39_pantr was used. Examples for the use of the multi-
ple sequence alignment tree are shown in Fig. A in S1 File. The subfamily definition of re-
ceptors is shown within the yellow mark in Fig. A in S1 File.
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(6) Placement of interaction features: Interaction features were positioned for each rotamer in-
side the pocket volume according to the rotamer likelihood and ligand binding likelihood
of the residue. Both have been performed using default settings.
(7) Pharmacophore hypothesis generation: Interaction feature densities were clustered to gen-
erate pharmacophore features. All features were generated using a fuzzy pharmacophore
algorithm with an Rc value of 2.5 Å.[30] The top three features for hydrophobic, donor
and acceptor properties were selected and comprise the final pharmacophore.
(8) Pharmacophore validation: Three validation sets (see Compound datasets and prepara-
tion) were screened with all possible pharmacophore feature combinations containing 5
out of 9 or 6 out of 9 features, to identify the compounds that fit into the
pharmacophore model.
Compound datasets and preparation
Three sets of compounds were used for validating the structure-based pharmacophore model:
lab set, literature set, and blockers. The first two sets included hTAS2R39 agonists and com-
pounds which were inactive on hTAS2R39; the last set included so-called hTAS2R39 blockers.
The lab set (Table A in S1 File) is a set of flavonoids (2-phenyl benzopyrans) and isoflavonoids
(3-phenyl benzopyrans) tested for activation of bitter receptor hTAS2R39 in our laboratory.[4]
This set consisted of 66 active and 19 inactive compounds. The literature set (Table B in S1
File) was based on data obtained by others in various studies and contained chemically diverse
compounds (26 actives, 65 inactives).[1,31,32,33,34,35] Compounds reported as inactive on
hTAS2R39 were only included in the literature set, if they were tested at sufficiently high maxi-
mal concentrations ( 500 μM) in order to be in the same order of magnitude as inactive com-
pounds from the lab set. The blockers included three recently discovered compounds, which
reduced or eliminated activation of hTAS2R39 by receptor agonists.[6]
All compounds were prepared with MOE software from CCG (version 2012.10).[36] The
3D structures of the molecules were generated, partial charges (Gasteiger PEOE) were assigned,
and the database energy minimization protocol with force field MMFF94x was used to enforce
low energy conformations of the molecules. For the pharmacophore validation, multiple con-
formations of the compounds were needed, which can be subsequently fitted to the pharmaco-
phore model. The conformational search was performed with a stochastic search (Rejection
Limit 100, Iteration Limit 1000, RMS Gradient 0.005, MM Iteration Limit 200, Conformation
Limit 200).
Feature selection
In order to select the features that contribute most to the recognition of agonists from the lab
and literature set, the number of true positives (TP), false positives (FP), true negatives (TN),
and false negatives (FN) were calculated per pharmacophore validation. In addition, the recall
(recall = TP/(TP+FN)), precision (precision = TP/(TP+FP)) rates and the Matthews correla-
tion coefficient (MCC) (Equation 1) were calculated. The MCC ranges from -1 (no correlation)
to 1 (full correlation).
MCC ¼ ðTP  TN FP  FNÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃððTPþ FPÞðTPþ FNÞðTNþ FPÞðTNþ FNÞÞp ðEquation 1Þ
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Results and Discussion
Definition of bitter receptor binding pocket
For hTAS2R39, a structure based pharmacophore model was built (Fig. 1A) using only se-
quence conservation statistics and the structure of the transmembrane helices of a rhodopsin
subfamily structure. The binding pocket is located at the external site of the transmembrane re-
gion. This finding is in line with the known GPCR crystal structures of the rhodopsin subfamily
and it is also commonly accepted for the bitter taste receptors.[8,12,14,29,37] The binding
pocket is located between TM III, TM V, TM VI and TM VII. The amino acids contributing to
the binding site are listed in Table 1.
Pharmacophore model of the binding site
Based on the residues in the receptor binding site, the pharmacophore features were calculated
in Snooker. The calculation of the features was based on step (3) rotamer sampling and step (5)
residue scoring of the Snooker methodology.
Fig 1. Homology model of the TM domains of hTAS2R39. TM I is depicted in dark blue, TM II in light blue, TM III in cyan, TM IV in light green, TM V in
yellow, TM VI in orange, and TM VII in red. A) The Snooker pharmacophore hypothesis consists of acceptor features (numbers 0, 1, and 2 in gray), donor
features (numbers 3, 4, and 5 in green), and hydrophobic features (numbers 6, 7, and 8 in magenta). Residues contributing toB) acceptor and donor features
(0, 3, and 5) andC) hydrophobic features (6, and 8) of the best performing feature combination are shown as sticks. All common rotamers are shown.
doi:10.1371/journal.pone.0118200.g001
Table 1. Snooker pharmacophore features. Feature type, feature number, radius and residue contributions by amino acid number.
Feature Feature
number
Radius
[Å]
Residue number and contribution to feature
Acceptor 0 1.80 T5.45, 1.00
Acceptor 1 0.97 N5.40, 0.88; H4.56, 0.13
Acceptor 2 0.98 N7.39, 0.75; Q7.35, 0.25
Donor 3 1.82 T5.45, 0.81; N3.36, 0.13; N5.40, 0.06
Donor 4 2.16 N5.40, 0.82; H4.56, 0.18
Donor 5 2.10 N7.39, 1.00
Hydrophobic 6 3.32 V6.52, 0.28; I6.48, 0.16; L3.40, 0.15; L5.41, 0.11; F6.55, 0.10; F3.37, 0.06; V5.44, 0.05; I6.56, 0.04; F3.32,
0.03; A6.51, 0.01; Y7.45, 0.01
Hydrophobic 7 2.84 V5.44, 0.37; I3.33, 0.28; F3.37, 0.17; L5.41, 0.10; F6.55, 0.06; L3.40, 0.01
Hydrophobic 8 2.75 F6.55, 0.45; I3.33, 0.43; L5.41, 0.09; F3.32, 0.04
doi:10.1371/journal.pone.0118200.t001
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All common rotamers for alpha-helix residues (Fig. 1B,C) were considered and the density
of interaction features surrounding a rotamer was weighted according to their true existence in
alpha-helices of experimentally derived structures. In addition, the Snooker residue scoring
had influence on the density of the interaction feature placement. The residue scoring in
Snooker is based on the assumption that residues involved in ligand binding are conserved
within a subfamily. For residues with a high conservation score the density of interaction fea-
tures is larger than for residues with a lower score.
The interaction features obtained were subsequently translated into a pharmacophore hy-
pothesis (Fig. 1A). For each feature type (acceptor, donor and hydrophobic) the top three fea-
tures were generated. A list with the contribution of the amino acid residues to each feature can
be found in Table 1. The hydrogen bond acceptor and donor features were assigned to only a
few residues in the binding site (Fig. 1B, Table 1). The hydrophobic features of the pharmaco-
phore model were based on up to 11 residues and had a radius of 2.75–3.32 Å (Fig. 1C,
Table 1). These features seemed to describe the overall shape of the compounds that can bind
to the receptor. Besides hydrophobic interactions, aromatic residues (F3.32, F6.55) could inter-
act with the compounds via π-stacking. This is in line with the nature of protein-ligand interac-
tions. Hydrogen bonds are very specific and occur at specific distances and angles, as a result of
which acceptor and donor features comprise 1–3 residues. Hydrophobic interactions are less
defined in their shape and direction, leading to larger hydrophobic features with 4–11 residues.
Pharmacophore validation
Considering Snooker applications in the past, the binding site can be best described by 5–6 fea-
tures. For the pharmacophore validation, all feature combinations with 5 out of 9 features or 6
out of 9 features were used. If all 9 features were to be mapped, the number of hits would be
limited to only a few compounds, most likely many other compounds with potential for unrav-
elling the hTAS2R39 binding pocket would have been missed. As measure for the quality of the
pharmacophore validation recall, precision and the Matthews correlation coefficient (MCC)
were calculated. All results which had a recall of more than 50% (Table 2, Tables C-E in S1
File) were further evaluated.
Comparing the results of 5 and 6 feature pharmacophores, it turned out that the overall per-
formance was better for the 5 featured pharmacophores (Fig. 2, Table 2). The 6 feature phar-
macophores are probably too specific to certain ligand classes (and restrict ligands too much),
whereas the 5 feature pharmacophores capture the key binding modes, while still allowing for
some variation in the ligands.
Based on the better results for 5 feature pharmacophores, we analyzed these in more detail.
The best performing set of features for the lab set (Table 2) was [0, 3, 6, 7, 8] (recall: 91%, preci-
sion: 89%, MCC: 0.51) and for the literature set (Table 2) was [0, 1, 6, 7, 8] (recall: 69%,
Table 2. Best pharmacophore validation results per set and 5 or 6 feature combination.
Compound set Feature set Recall Precision MCC
lab set [0, 3, 6, 7, 8] 0.91 0.89 0.51
[0, 3, 5, 6, 7, 8] 0.73 0.96 0.48
literature set [0, 1, 6, 7, 8] 0.69 0.74 0.61
[0, 1, 4, 6, 7, 8] 0.58 0.87 0.35
combined set [0, 3, 5, 6, 8] 0.63 0.97 0.44
[0, 3, 5, 6, 7, 8] 0.61 0.97 0.44
doi:10.1371/journal.pone.0118200.t002
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precision: 74%, MCC: 0.61). Both pharmacophores were similar and shared 4 of the 5 features.
It is known that different ligands often share a core of ligand-binding amino acid residues, but
non-overlapping binding features occur as well.
Combining both the lab and literature set (Table 2) allowed determination of the feature
combination, giving the best validation results. Best validation results were obtained for feature
combination [0, 3, 5, 6, 8] (recall: 63%, precision: 97%, MCC: 0.44) (Fig. 2). Based on the com-
bined pharmacophore validation results, the features most selective in compound recognition
were features 0, 3 and 5. Hydrogen bond acceptor feature 0 refers to residue T5.45, hydrogen
bond donor feature 3 refers to residue T5.45, N3.36 and N5.40 and hydrogen bond donor fea-
ture 5 refers to N7.39. With 81%, T5.45 (Table 1) contributed most to feature 3, although
N3.36 and N5.40 contributed as well. This resulted in the location of feature 3 at the bottom of
the binding site. Without the contribution of N3.36 and N5.40, feature 3 and feature 0 would
coincide (Fig. 1B and 3A). Feature 5 was located at the top of the binding site.
Fig 2. Pharmacophore results plot. 5 feature pharmacophore lab set (black x), 5 feature pharmacophore literature set (green circle), 5 featured combined
set (magenta plus), 6 feature pharmacophore lab set (red circle), 6 feature pharmacophore literature set (cyan box) and 6 featured combined set (orange
diamond).
doi:10.1371/journal.pone.0118200.g002
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GPCRs which have been co-crystalized with agonists show that deep in the pocket between
TM III, IV, V, VI, and VII the activation trigger is positioned. One example is the activation of
the beta-1 adrenergic receptor (b1-AR), triggered by the interaction to S5.42 in TM V.[37] In
the case of the Snooker hTAS2R39 model, T5.45 is located at this position (the numbering is
shifted by 3 positions, as the beginning of helix V was adjusted, see methods) and might be the
key residue for receptor activation. Interestingly, there are also similarities in key amino acids
for ligand recognition found with our model and those in two other bitter taste receptors. Beh-
rens et al. mentioned the importance of N3.36, which is probably involved in binding of ago-
nists to hTAS2R16, -30, -38 and -46, and of residues close to N3.36 (L3.32, L3.33 and E3.37),
which are involved in binding to hTAS2R1.[38] Furthermore, it was proposed that W3.32,
Fig 3. Selection of compounds fitted into the pharmacophore. A) Fitting of agonist kaempferol (gray) into the pharmacophore features 0, 3, 5, 6, 8.
Residues, which make hydrogen bonds to the agonist, are shown as sticks.B) Fitting of the blocker 4’-fluoro-6-methoxyflavanone (S-enantiomer, blue) into
the pharmacophore features 0, 1, 2, 7, 8. Residues, which make hydrogen bonds (yellow dashes) to the blocker, are shown as sticks.C) Fitting of kaempferol
(gray), luteolin (pink), naringenin (green), and epicatechin (cyan). D) Fitting of the kaempferol (gray) and 4’-fluoro-6-methoxyflavanone (blue). The structures
of 4’-fluoro-6-methoxyflavanone, luteolin, naringenin, and epicatechin are shown in Fig. 4.
doi:10.1371/journal.pone.0118200.g003
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A3.33, N3.36, H3.37, and N3.40 were key residues for ligand interaction with hTAS2R31, -43,
and -46,[18] and S3.29, W3.32, V3.33, N3.36, Q5.40, and L5.43 for ligand interaction with
hTAS2R10.[10] Although there is striking similarity in key residues (or TM regions) involved
in ligand binding in hTAS2R39 and other hTAS2Rs, the residues do not need to be identical, as
has been demonstrated for GPCRs of the rhodopsin subfamily, where different amino acids
were important for ligand binding and activation in various representatives.[26]
Comparison of structure-based pharmacophore model to ligand-based
pharmacophore model
In a previous study, ligand-based pharmacophore models were developed for isoflavonoids
and flavonoids with respect to hTAS2R39.[4] The best results for the ligand-based model were
achieved for a 6-feature pharmacophore, which allowed the ligands to map 5 of 6 features and
comprised of three hydrogen bond donor sites, one hydrogen bond acceptor site, and two aro-
matic ring structures, of which one had to be hydrophobic.
Comparison of ligand-based and structure-based pharmacophore models revealed that the
results were similar and ligand-based and structure-based models overlapped regarding the oc-
currence of the following 5 features: 1 hydrogen bond acceptor (feature 0), 2 hydrogen bond
donors (feature 3, 5), and 2 hydrophobic features (feature 6, 8). In case of the ligand-based
model, better results were obtained with in total three donor features and the possibility to
miss one of the six features, and in case of the structure-based model, better results were ob-
tained with in total three hydrophobic features.
Regarding size, both models were comparable as well. The distance between the two hydro-
phobic features in the ligand-based model was 6.8 Å, and in the structure-based model 6.7 Å.
The two features furthest apart in the ligand-based model were two hydrogen bond donors
with a distance of 10.7 Å. In the structure-based model the two features furthest apart were 3
and 5 with a distance of 12.8 Å.
Comparison of the best models for the lab set revealed that both approaches led to very
good results. The performance of the ligand-based model (recall: 86%, precision: 95%, MCC:
0.57) was even slightly better than that of the structure-based model (recall: 91%, precision:
89%, MCC: 0.51). Nevertheless, the ligand-based model was limited to the use for isoflavo-
noids, flavonoids and structurally closely related compounds. The structure-based model offers
broader applicability to structurally diverse bitter receptor agonists. Furthermore, the struc-
ture-based model can account for two binding modes, agonist and antagonist (or blocker), to-
gether with their respective interacting amino acids, as will be described below.
Blocker binding
The three compounds 4’-fluoro-6-methoxyflavanone, 6,3’-dimethoxyflavanone, and 6-meth-
oxyflavanone (in decreasing order of potency, depicted in Fig. 4) have been reported as block-
ers of hTAS2R39.[6] These compounds decreased or eliminated the activation of hTAS2R39
by several agonists, suggesting that they bind to the receptor without activating it. The blocker
molecules are characterized by lacking a double bond in the C-ring between atoms 2 and 3
(subclass ‘flavanones’). This results in a tetrahedral conformation at atom 2 for the blockers
compared to most agonists, which are planar at this position (Fig. 3B,C). Besides lacking the
C-ring double bond, it is important to note that flavanones were only functional as blockers
when they possessed a methoxy group at atom 6 (e.g. a methoxy group at atom 7 or a hydroxyl
group at atom 6 did not result in blocking).
With respect to the results of the 5 and 6 features pharmacophore validation (Table F in S1
File), all blockers could be fitted into the pharmacophore model containing up to three
Snooker Explains Differences in hTAS2R39 Agonist and Blocker Binding
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hydrogen bond acceptor features and three hydrophobic features. In general, the S-enantiomer
could more often be fitted into the pharmacophore model than the R-enantiomer. However, it
could not be verified whether the R-enantiomer is inactive, as a racemic mixture of 4’-fluoro-6-
methoxyflavanone, 6,3’-dimethoxyflavanone, and 6-methoxyflavanone was used in the recep-
tor assay.
Agonists and blockers share fitting to feature 0, which indicates an interaction to T5.45 and
feature 6 and 8, which fits the hydrophobic core of the molecules. Due to the stereocenter intro-
duced, the blockers were placed crooked into the pharmacophore and not linear as most of the
agonists (Fig. 3B). Reviewing the properties of the blockers showed that they had no hydrogen
bond donor. This was in contrast to all hTAS2R39 agonists, which comprised at least one hy-
drogen bond donor (with the exception of two compounds, flavone and xanthone). Lacking a
hydrogen bond donor, the blockers did not map to feature 3, which seemed important for re-
ceptor activation. As displayed in Fig. 3B, the hydrogen bond acceptor groups of the blocker
fitted optimally into the hydrogen bond acceptor features of the pharmacophore model with
features [0, 1, 2, 7, 8]. This positioning allowed 4’-fluoro-6-methoxyflavanone and 6,3’-
dimethoxyflavanone to make a hydrogen bond to Q7.35 and/or N7.39 (Fig. 3B). Moreover, the
blockers could interact with the side chain of F6.55 by forming hydrophobic interactions (not
shown in Fig. 3B). These interactions could explain the different strength of the blockers
(fluoro>methoxy> hydrogen). If both interactions occurred, hydrophobic interaction with
F6.55 and hydrogen bonding with Q7.35 / N7.39, the blocker appeared to be more potent
than if only one interaction was possible. In addition, the hydrogen bond of 4’-fluoro-6-
methoxyflavanone is stronger and in a better angle to the protein than the one of 6,3’-
dimethoxyflavanone.
Fig 4. Structures of hTAS2R39 blockers (A-C) and agonists (D-F). 4’-fluoro-6-methoxyflavanone (A), 6,3’-
dimethoxyflavanone (B), 6-methoxyflavanone (C), luteolin (D), naringenin (E), and epicatechin (F). Flavonoid-
specific ring nomenclature (A/B/C-ring) and the atom numbers are illustrated in (A).
doi:10.1371/journal.pone.0118200.g004
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Considering flavonoids, the difference between agonists and blockers is determined by pla-
narity of the ring structures, in combination with the occurrence of hydrogen bond donors.
Fig. 3C shows kaempferol, luteolin, naringenin, and epicatechin, compounds with excellent ag-
onistic properties on hTAS2R39.[4] Thus, not all non-linear molecules are blockers, as e.g. fla-
vanols are hTAS2R39 agonists, due to their hydrogen bond donor groups. The absence of
hydrogen bond donors in combination with a crooked position of the molecule in the binding
site are prerequisites for blocking properties on hTAS2R39 (Fig. 3D).
For rhodopsin subfamily GPCRs, it is known that the TM domains around the extracellular
ligand binding site are tightened up upon agonist binding, which goes along with a conforma-
tional change of the TM domains on the intracellular side. These conformational changes are
important for receptor activation.[37] Upon blocker binding to rhodopsin subfamily GPCRs,
the contraction of the TM domains in the binding site is sterically hindered. For the taste recep-
tors a similar conformational change for receptor activation might be expected. Based on the
structure-based pharmacophore model of hTAS2R39, we can propose that the blockers studied
behave very similar to rhodopsin subfamily blockers. The crooked binding mode of the block-
ers, which is stabilized by the three (or less) hydrogen bonds (Fig. 3B) to the receptor, can hin-
der the conformational change in the TM domains, which is needed for receptor activation.
Conclusion
With the structure-based pharmacophore model derived with Snooker details about receptor
binding sites at a molecular level can be proposed, which are in accordance to amino acids
mentioned in related studies. Furthermore, the structure-based pharmacophore model gives
insight into the differences of agonist and blocker binding. The structure-based model has
been validated with large sets of previously published compounds (two large sets of agonists
and inactive compounds, and one small set of blockers, as only few blockers are known). As
these compounds were not used to build the model, they are suited as retro perspective experi-
mental validation of the structure-based pharmacophore model. Our structure-based pharma-
cophores overlap with previously generated ligand-based pharmacophores, suggesting that we
have indeed successfully identified the key interaction features of the hTAS2R39 receptor. This
enabled us to generate a pose of each hTAS2R39 compound and optimize these by optimizing
the interactions. Our pharmacophore model shows that flavonoid-derived blockers bind differ-
ently to the receptor than (iso)flavonoid-based agonists. Due to the tetrahedral conformation
of the C-ring carbons 2 and 3, a crooked position of the molecule in the binding site is forced.
In combination with the absence of hydrogen bond donors, this geometry leads to blocking
properties, the strength of which is influenced by interaction with amino acid residues on the
upper side of the binding pocket. Prospective validation of the model is desirable but not man-
datory to ensure the quality of the derived model, as the compounds were not used to build the
model. To verify all hypotheses about ligand binding and activation, complex site-directed mu-
tagenesis studies would have to be conducted which would include the different use of ligand
binding residues by the different ligands and the potentially different activation mechanism.
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